Phosphocreatine disodium
Based on 3 publication(s) in Google Scholar
Phosphocreatine (disodium) is an organic compound found in vertebrate skeletal muscles. Phosphocreatine (disodium) enhances antioxidant activity, and activates the TAK1 pathway to protect the heart. Phosphocreatine (disodium) normalizing mitochondrial function and reducing oxidative stress via Akt mediated Nrf2/HO-1 pathway. Phosphocreatine (disodium) provides renal protection by suppressing Apoptosis and ROS (Reactive Oxygen Species) generation through ERK mediated mediated Nrf-2/HO-1 pathway..
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.0%
- No. CAS: 922-32-7
- Fòrmula: C4H8N3Na2O5P
- Peso molecular:255.08
-
Almacenamiento:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-D0187
L-Glutathione reduced
-
HY-12695
Guanosine 5'-triphosphate trisodium
-
HY-P2799
Creatine phosphokinase, Rabbit muscle
-
HY-B1776
Spermidine
-
HY-107754
Cesium chloride
-
HY-K0202
Protein A/G Magnetic Beads
-
HY-B0504
Creatinine
-
HY-W017770
S-Adenosyl-L-methionine disulfate tosylate
-
HY-B1793
Tetraethylammonium chloride
-
HY-D0885BR
Phosphocreatine disodium (Standard)
-
HY-16637
Folic acid
-
HY-16450
SB 204990
Publications Citing Use of MedChemExpress (MCE) Phosphocreatine disodium
MoreVer todos los productos específicos de isoformas Endogenous Metabolite
MoreVer todos los productos específicos de isoformas MAP3K
More
Actividad biológica
|
Human Endogenous Metabolite |
Non-salt form:
Phosphocreatine (0-1 mM, 24 h) reveals the effect of anti-oxidant, anti-apoptosis and anti-necroptosis to protect agaist DOX (Doxorubicin) (HY-15142A)-induced cardiomyocytes injury in H9c2 cells by targeting TAK1[2].
Phosphocreatine (0-1 mM, 24 h) alleviates oxidative stress by increasing antioxidant activity, subsequently recovers expression level of TAK1 to baseline and reduces apoptosis and necroptosis in DOX-induced myocardial injury[2].
Phosphocreatine (5-20 mM, 24 h) attenuates cell injury and inhibits apoptosis induced by MGO (Methylglyoxal) (HY-106634) in PC12 cell[3].
Phosphocreatine (5-20 mM, 24 h) prevents loss of mitochondrial membrane permeability of MGO (Methylglyoxal) injured PC-12 cells[3].
Phosphocreatine (5-20 mM, 2 h) exhibits the neuroprotective effects in PC-12 cells relying on normalizing mitochondrial function and reducing oxidative stress via Akt mediated Nrf2/HO-1 pathway[3].
Phosphocreatine (5-40 mM, 24 h) at different concentrations might contribute to protection of the NRK-52E cells against MGO-induced kidney injury[4].
Phosphocreatine (10-40 mM, 4 h) suppresses kidney oxidative stress metabolites[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PC-12, NRK-52E cells
-
Concentration:5, 10, 20, 40 mM
-
Incubation Time:2 h
-
Result:Significantly suppressed the enhanced early apoptosis in PC-12 cells in a dose-dependent manner.
Increased the expression of Bcl-2, procaspase-3 and procaspase-9 in NRK-52E cells.
Decreased the expression of Bax and cleaved caspase-3 in NRK-52E cells.
Suppressed karyorrhexis and karyopyknosis in NRK-52E cells.
Decreased the apoptotic rate compared with MGO-treated cells in NRK-52E cells.
Prevented the losing of MMP (mitochondrial membrane potential) in NRK-52E cells.
-
Cell Line:PC-12, NRK-52E cells
-
Concentration:0, 5, 10, 20, 40 mM
-
Incubation Time:24 h
-
Result:Was not toxic to PC-12 cells under the treatment conditions.
Significantly increased PC-12 cell viability at the concentrations of 5, 10 and 20 mM compared with MGO (Methylglyoxal) (HY-106634) groups.
Contributed to protection of the NRK-52E cells against MGO-induced kidney injury.
-
Cell Line:PC-12, NRK-52E cells
-
Concentration:20, 40 mM
-
Incubation Time:24 h
-
Result:Increased the expression levels of Akt, Nrf2 (nuclear factor (erythroid-derived-2)-like 2 (Nrf2)) and HO-1 (Hemeoxygenase-1) in PC12 cells.
Increased the expression of nuclear Nrf2 levels, and decreased Nrf2 level in PC12 cells cytoplasm.
Increased the expression of p-Akt, HO-1 and Nrf2 with compared with pre-treatment for 2 h with LY294002 (a PI3K inhibitor) in PC12 cells.
Significantly increased Bcl-2 and procaspase-9 levels and decreased Bax, cleaved caspase-9 and cleaved caspase-3 C level in NRK-52E cells.
Decreased the expression of p-ERK and increased the Nrf2 and HO-1 expressions in NRK-52E cells.
Phosphocreatine (200 mg/kg, i.p., once every other day, 7 weeks) not only alleviates oxidative stress and myocardial apoptosis, but also rescues myocardial necroptosis in DOX-induced cardiotoxicity of rat[2].
Phosphocreatine (20-40 mg/kg, i.v., daily, 6 weeks) has a protective effect on the kidney tissues against diabetic nephropathy in SD (Sprague Dawley) rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague Dawley (SD) rats, i.p., normal saline, 3 times; i.p., DOX 2 mg/kg, 7 times; i.p., normal saline, 3 times [2]
-
Dosage:200 mg/kg
-
Administration:i.p., once every other day, 7 weeks
-
Result:Improved the heart function abnormality.
Lowered myocardial apoptosis.
Recovered the expression of Nrf2, SOD, FoxO3a and diminished C-Casp3, Bax/Bcl2 in the myocardial tissue of rats.
Markedly improved myocardial necroptosis, as indicated by decreasing expression of RIP3 and CaMKII.
Increased expression level of TAK1.
-
Animal Model:Male Sprague Dawley (SD) rats, i.p., 70 mg/kg (STZ(Streptozotocin) (HY-13753)), daily, 6 weeks [4]
-
Dosage:20, 40 mg/kg
-
Administration:i.p., daily, 6 weeks
-
Result:Reduced hyperglycemia compared with STZ (Streptozotocin) (HY-13753) -treated rats.
Increased the weight of rats gradually compared with STZ (Streptozotocin) (HY-13753) group.
Decreased kidney weight index (kidney weight/body weight).
Decreased MDA level and increased of GSH and SOD levels compared with STZ group.
Decreased the apoptotic rate compared with MGO-treated groups.
Chemical Information
-
No. CAS 922-32-7
-
Appearance Solid
-
Peso molecular 255.08
-
Fòrmula C4H8N3Na2O5P
-
Color White to off-white
-
SMILES
O=C(O)CN(C(NP(O[Na])(O[Na])=O)=N)C
-
Synonyms
Disodium creatine phosphate
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
ESCRT III-mediated lysosomal repair improve renal tubular cell injury in cisplatin-induced AKI. [Abstract]2025 Sep;21(9):1927-1944. PMID: 40152606 -
-
Toxicol Appl Pharmacol
2022 Apr 15:441:115971. PMID: 35276125
Solvente y solubilidad
H2O : 125 mg/mL (490.04 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (392.03 mM); Clear solution; Need ultrasonic
Pureza y Documentación
-
Ficha de datos (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Feldman EB, et al. Creatine: a dietary supplement and ergogenic aid. Nutr Rev. 1999 Feb;57(2):45-50. [Content Brief]
[2]. Wang C, et al. Phosphocreatine attenuates doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and activating TAK1 to promote myocardial survival in vivo and in vitro. Toxicology. 2021 Aug;460:152881. [Content Brief]
[3]. Li H, et al. Neuroprotective effect of phosphocreatine on oxidative stress and mitochondrial dysfunction induced apoptosis in vitro and in vivo: Involvement of dual PI3K/Akt and Nrf2/HO-1 pathways. Free Radic Biol Med. 2018 May 20;120:228-238. [Content Brief]
[4]. Shopit A, et al. Protection of diabetes-induced kidney injury by phosphocreatine via the regulation of ERK/Nrf2/HO-1 signaling pathway. Life Sci. 2020 Feb 1;242:117248. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 3.9203 mL | 19.6017 mL | 39.2034 mL | 98.0085 mL |
| 5 mM | 0.7841 mL | 3.9203 mL | 7.8407 mL | 19.6017 mL | |
| 10 mM | 0.3920 mL | 1.9602 mL | 3.9203 mL | 9.8008 mL | |
| 15 mM | 0.2614 mL | 1.3068 mL | 2.6136 mL | 6.5339 mL | |
| 20 mM | 0.1960 mL | 0.9801 mL | 1.9602 mL | 4.9004 mL | |
| 25 mM | 0.1568 mL | 0.7841 mL | 1.5681 mL | 3.9203 mL | |
| 30 mM | 0.1307 mL | 0.6534 mL | 1.3068 mL | 3.2669 mL | |
| 40 mM | 0.0980 mL | 0.4900 mL | 0.9801 mL | 2.4502 mL | |
| 50 mM | 0.0784 mL | 0.3920 mL | 0.7841 mL | 1.9602 mL | |
| 60 mM | 0.0653 mL | 0.3267 mL | 0.6534 mL | 1.6335 mL | |
| 80 mM | 0.0490 mL | 0.2450 mL | 0.4900 mL | 1.2251 mL | |
| 100 mM | 0.0392 mL | 0.1960 mL | 0.3920 mL | 0.9801 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Phosphocreatine disodium Related Classifications
HY-D0885B Related Classifications
Powered by Bioz